Get started
Author

Michael E. Petrone

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
2009 · Cora N. Sternberg, Daniel P. Petrylak, et al. · Journal of Clinical Oncology · 340
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
2017 · Shyamala C. Navada, Steven M. Fruchtman, et al. · Leukemia Research · 44
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail
2017 · Christopher R. Cogle, Sandra E. Kurtin, et al. · The Oncologist · 21
PDF
Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation
2001 · William J Lane, Koichi Hattori, et al. · Experimental Hematology · 18
Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study
2009 · Alejandro D. Ricart, John Sarantopoulos, et al. · Clinical Cancer Research · 15
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients
2018 · Shyamala C. Navada, Guillermo Garcia-Manero, et al. · Blood · 14
Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents
2014 · Erin P. Demakos, Lewis R. Silverman, et al. · Blood · 10
The Diagnosis of Dementia: Demographic Characteristics
1990 · A. C. Coyne, H. M. Meade, et al. · The Gerontologist · 9
Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies
2014 · Sudipto Mukherjee, Christopher R. Cogle, et al. · Blood · 6
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study
2016 · Shyamala C. Navada, Guillermo Garcia-Manero, et al. · Blood · 4
Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
2016 · Guillermo Garcia-Manero, Pierre Fenaux, et al. · Blood · 4
Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy
2015 · Christopher R Cogle, Jesse D Ortendahl, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 4
Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy
2014 · Christopher R. Cogle, Sudipto Mukherjee, et al. · Blood · 4
Satraplatin: A new treatment option for patients with hormone refractory prostate cancer
2005 · F. E. Nathan, C. Sternberg, et al. · Journal of Clinical Oncology · 4
Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials
2018 · Manoj Maniar, Chen Ren, et al. · Blood · 3
Rigosertib in myelodysplastic syndromes (MDS)
2016 · A. Raza, A. M. Ali, et al. · Expert Opinion on Orphan Drugs · 2
112 Randomized Phase Iii Study of Iv Rigosertib Versus Best Supportive Care (bsc) in Patients With Higher-risk Mds (hr-mds) After Failure of Hypomethylating Agents (hmas)
2015 · G. Garcia-Manero, P. Fenaux, et al. · Leukemia Research · 2
Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial
2009 · A. O. Sartor, D. Petrylak, et al. · Journal of Clinical Oncology · 2
A phase I study of the oral platinum agent satraplatin (S) in with capecitabine (C) in patients (pts) with advanced solid malignancies
2008 · K. Wisinski, M. Mulcahy, et al. · Journal of Clinical Oncology · 2
Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer
2006 · R. F. Setlik, G. Preston, et al. · Journal of Clinical Oncology · 2
Epidemiology of congenital syphilis.
1989 · M E Petrone, M J Teter, et al. · PubMed · 2
S839 Phase Ii Study of Oral Rigosertib Combined With Azacitidine in Patients With Higher‐risk Myelodysplastic Syndromes (mds)
2019 · S.C. Navada, G. Garcia‐Manero, et al. · HemaSphere · 1
Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine
2018 · David Taft, Tarang Vora, et al. · Blood · 1
Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA).
2017 · Aref Al-Kali, Devendra Hiwase, et al. · Journal of Clinical Oncology · 1
Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome.
2015 · Lewis R. Silverman, Pierre Fenaux, et al. · Journal of Clinical Oncology · 1
Works count: 43
Citation count: 520
H-index: 8
I10-index: 7
Year
Topic
Type